Glucose-insulin-potassium revived: Current status in acute coronary syndromes and the energy-depleted heart

Circulation

Volumn 127, Issue 9, 2013, Pages 1040-1048

  Grossman, Alexandra N ^a   Opie, Lionel H ^b   Beshansky, Joni R ^a   Ingwall, Joanne S ^c   Rackley, Charles E ^d   Selker, Harry P ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; GLUCOSE; INSULIN; POTASSIUM;

ACUTE CORONARY SYNDROME; GLUCOSE METABOLISM; GLYCOLYSIS; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEATOSIS;

ACUTE CORONARY SYNDROME; ANIMALS; CARDIOPLEGIC SOLUTIONS; GLUCOSE; HUMANS; INSULIN; METABOLIC NETWORKS AND PATHWAYS; MYOCARDIUM; POTASSIUM;

EID: 84874635113     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.130625     Document Type: Review

References (101)

1. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart, II: studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504-515.
2. Shipp JC, Opie LH, Challoner D. Fatty acid and glucose metabolism in the perfused heart. Nature. 1961;189:1018-1019.
3. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A. Effects of an intravenous infusion of a potassiumglucose-insulin solution on the electrocardiographic signs of myocardial infarction: a preliminary clinical report. Am J Cardiol. 1962;9:166-181.
4. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fattyacid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
5. Mittra B. Potassium, glucose, and insulin in treatment of myocardial infarction. Lancet. 1965;2:607-609.
6. Kurien VA, Oliver MF. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet. 1966;2:122-127.
7. Gupta DK, Jewitt DE, Young R, Hartog M, Opie LH. Increased plasmafree-fatty-acid concentrations and their significance in patients with acute myocardial infarction. Lancet. 1969;2:1209-1213.
8. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest. 1971;50:1386-1389.
9. Taylor SH, Majid PA. Insulin and the heart. J Mol Cell Cardiol. 1971;2:293-317.
10. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, Covell JW, Braunwald E. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation. 1972;45:1160-1175.
11. Opie LH, Bruyneel K, Owen P. Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon. Circulation. 1975;52:49-57.
12. Stanley AW Jr, Moraski RE, Russell RO, Rogers WJ, Mantle JA, Kreisberg RA, McDaniel HG, Rackley CE. Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease: studies on myocardial carbohydrate, lipid and oxygen arterialcoronary sinus differences in patients with coronary artery disease. Am J Cardiol. 1975;36:929-937.
13. Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium: effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res. 1983;52:515-526.
14. Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation. 2008;117:2523-2533.
15. Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, Wagg CS, Jaswal JS, Harris RA, Clanachan AS, Dyck JR, Lopaschuk GD. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res. 2012;94:359-369.
16. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, Kato T, Khan R, Takayama H, Knl R, Milting H, Chung CS, Jorde U, Naka Y, Mancini DM, Goldberg IJ, Schulze PC. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation. 2012;125:2844-2853.
17. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925-1933.
18. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, Eberli FR. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation. 2000;101:2090-2096.
19. Lown B, Fakhro AM, Hood WB Jr, Thorn GW. The coronary care unit: new perspectives and directions. JAMA. 1967;199:188-198.
20. Ussher JR, Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res. 2008;79:259-268.
21. Opie LH. Heart Physiology, From Cell to Circulation. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:308.
22. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207-258.
23. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278:H1345-H1351.
24. Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction: relation to myocardial ischemia and infarct size. Am J Cardiol. 1975;36:938-953.
25. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225-246.
26. King LM, Opie LH. Glucose and glycogen utilisation in myocardial ischemia: changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 1998;180:3-26.
27. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-319.
28. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122:2538-2544.
29. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793-1799.
30. Kjekshus JK, Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest. 1972;51:1767-1776.
31. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun. 2009;389:211-216.
32. Tansey MJ, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet. 1983;2:419-422.
33. Taegtmeyer H, Goodwin GW, Doenst T, Frazier OH. Substrate metabolism as a determinant for postischemic functional recovery of the heart. Am J Cardiol. 1997;80(3A):3A-10A.
34. Lopaschuk GD. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischemia. Am J Cardiol. 1997;80(3A):11A-16A.
35. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther. 1993;264:135-144.
36. Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol. 2002;39:718-725.
37. Kurien VA, Oliver MF. A metabolic cause for arrhythmias during acute myocardial hypoxia. Lancet. 1970;1:813-815.
38. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996;78:1350-1354.
39. Corr PB, Gross RW, Sobel BE. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res. 1984;55:135-154.
40. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23(suppl 1):11-22.
41. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. 2000;279:H2124-H2132.
42. Korge P, Honda HM, Weiss JN. Effects of fatty acids in isolated mitochondria: implications for ischemic injury and cardioprotection. Am J Physiol Heart Circ Physiol. 2003;285:H259-H269.
43. Li N, Wang J, Gao F, Tian Y, Song R, Zhu SJ. The role of uncoupling protein 2 in the apoptosis induced by free fatty acid in rat cardiomyocytes. J Cardiovasc Pharmacol. 2010;55:161-167.
44. Tominaga H, Katoh H, Odagiri K, Takeuchi Y, Kawashima H, Saotome M, Urushida T, Satoh H, Hayashi H. Different effects of palmitoyl-Lcarnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;295:H105-H112.
45. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res. 2006;47:2726-2737.
46. Fang KM, Lee AS, Su MJ, Lin CL, Chien CL, Wu ML. Free fatty acids act as endogenous ionophores, resulting in Na+ and Ca2+ influx and myocyte apoptosis. Cardiovasc Res. 2008;78:533-545.
47. Rackley CE, Russell RO Jr, Rogers WJ, Mantle JA, McDaniel HG, Papapietro SE. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J. 1981;102(pt 1):1038-1049.
48. McDaniel HG, Papapietro SE, Rogers WJ, Mantle JA, Smith LR, Russell RO Jr, Rackley CE. Glucose-insulin-potassium induced alterations in individual plasma free fatty acids in patients with acute myocardial infarction. Am Heart J. 1981;102:10-15.
49. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994;35:177-193.
50. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet. 1994;343:155-158.
51. Rooyen JV, McCarthy J, Opie LH. Increased glycolysis during ischaemia mediates the protective effect of glucose and insulin in the isolated rat heart despite the presence of exogenous substrates. Cardiovasc J South Africa. 2002;13:103-109.
52. King LM, Boucher F, Opie LH. Coronary flow and glucose delivery as determinants of contracture in the ischemic myocardium. J Mol Cell Cardiol. 1995;27:701-720.
53. Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res. 1991;68:466-481.
54. Vanoverschelde JL, Janier MF, Bakke JE, Marshall DR, Bergmann SR. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol Heart Circ Physiol. 1994;267:H1785-H1794.
55. Mallet RT, Hartman DA, Bger R. Glucose requirement for postischemic recovery of perfused working heart. Eur J Biochem. 1990;188:481-493.
56. Bricknell OL, Opie LH. Effects of substrates on tissue metabolic changes in the isolated rat heart during underperfusion and on release of lactate dehydrogenase and arrhythmias during reperfusion. Circ Res. 1978;43:102-115.
57. Dhar-Chowdhury P, Malester B, Rajacic P, Coetzee WA. The regulation of ion channels and transporters by glycolytically derived ATP. Cell Mol Life Sci. 2007;64:3069-3083.
58. Murphy E, Steenbergen C. Ion transport and energetics during cell death and protection. Physiology (Bethesda). 2008;23:115-123.
59. Jeremy RW, Ambrosio G, Pike MM, Jacobus WE, Becker LC. The functional recovery of post-ischemic myocardium requires glycolysis during early reperfusion. J Mol Cell Cardiol. 1993;25:261-276.
60. Jeremy RW, Koretsune Y, Marban E, Becker LC. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res. 1992;70:1180-1190.
61. Clanachan AS. Contribution of protons to post-ischemic Na(+) and Ca(2+) overload and left ventricular mechanical dysfunction. J Cardiovasc Electrophysiol. 2006;suppl 1:S141-S148.
62. Zhang HX, Zang YM, Huo JH, Liang SJ, Zhang HF, Wang YM, Fan Q, Guo WY, Wang HC, Gao F. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharmacol. 2006;48:306-313.
63. Opie LH, Tansey M, Kennelly BM. Proposed metabolic vicious circle in patients with large myocardial infarcts and high plasma-free-fatty-acid concentrations. Lancet. 1977;2:890-892.
64. Tansey MJ, Opie LH. Plasma glucose on admission to hospital as a metabolic index of the severity of acute myocardial infarction. Can J Cardiol. 1986;2:326-331.
65. Sinha DP, Ahmed S, Baneerjee AK, Das M, Hassan H. Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome. Indian Heart J. 2009;61:40-43.
66. DeBoer LW, Rude RE, Kloner RA, Ingwall JS, Maroko PR, Davis MA, Braunwald E. A flow-and time-dependent index of ischemic injury after experimental coronary occlusion and reperfusion. Proc Natl Acad Sci USA. 1983;80:5784-5788.
67. Gibson MC, Pride YB, Frederick PD, Pollack CV Jr, Canto JG, Tiefenbrunn AJ, Weaver WD, Lambrew CT, French WJ, Peterson ED, Rogers WJ; NRMI Investigators. Trends in reperfusion strategies, doorto-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008;156:1035-1044.
68. Prasad A, Stone GW, Holmes DR, Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation. 2009;120:2105-2112.
69. Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J. 2005;26:956-959.
70. Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation. 2008;117:2172-2177.
71. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, Covell JW, Braunwald E. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation. 1972;45:1160-1175.
72. Sybers HD, Maroko PR, Ashraf M, Libby P, Braunwald E. The effect of glucose-insulin-potassium on cardiac ultrastructure following acute experimental coronary occlusion. Am J Pathol. 1973;70:401-420.
73. Dalby AJ, Bricknell OL, Opie LH. Effect of glucose-insulin-potassium infusions on epicardial ECG changes and on myocardial metabolic changes after coronary artery ligation in dogs. Cardiovasc Res. 1981;15:588-598.
74. Angelos MG, Murray HN, Gorsline RT, Klawitter PF. Glucose, insulin and potassium (GIK) during reperfusion mediates improved myocardial bioenergetics. Resuscitation. 2002;55:329-336.
75. Jonassen AK, Aasum E, Riemersma RA, Mj OD, Larsen TS. Glucoseinsulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther. 2000;14:615-623.
76. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebocontrolled trials. Circulation. 1997;96:1152-1156.
77. Yazici M, Demircan S, Durna K, Yasar E, Acar Z, Sahin M. Effect of glucose-insulin-potassium infusion on myocardial damage due to percutaneous coronary revascularization. Am J Cardiol. 2005;96:1517-1520.
78. Chaudhuri A, Janicke D, Wilson M, Ghanim H, Wilding GE, Aljada A, Dandona P. Effect of modified glucose-insulin-potassium on free fatty acids, matrix metalloproteinase, and myoglobin in ST-elevation myocardial infarction. Am J Cardiol. 2007;100:1614-1618.
79. Bucciarelli-Ducci C, Bianchi M, De Luca L, Battagliese A, Di Russo C, Proietti P, Vizza CD, Fedele F. Effects of glucose-insulin-potassium infusion on myocardial perfusion and left ventricular remodeling in patients treated with primary angioplasty for ST-elevation acute myocardial infarction. Am J Cardiol. 2006;98:1349-1353.
80. Krljanac G, Vasiljevi Z, Radovanovi M, Stankovi G, Mili N, Stefanovi B, Kosti J, Mitrovi P, Radovanovi N, Dragovi M, Marinkovi J, Karadzi A. Effects of glucose-insulin-potassium infusion on ST-elevation myocardial infarction in patients treated with thrombolytic therapy. Am J Cardiol. 2005;96:1053-1058.
81. Malmberg K, Ryd L, Efendic S, Herlitz J, Nicol P, Waldenstr A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
82. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-1515.
83. Dz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corval R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction: the ECLA (Estudios Cardiolicos Latinoamica) Collaborative Group. Circulation. 1998;98:2227-2234.
84. CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437-446.
85. Timmer JR, Svilaas T, Ottervanger JP, Henriques JP, Dambrink JH, van den Broek SA, van der Horst IC, Zijlstra F. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol. 2006;47:1730-1731.
86. Parikh SV, Abdullah SM, Keeley EC, Cigarroa JE, Addo TA, Warner JJ, Khera A, de Lemos JA, McGuire DK. Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK. Diab Vasc Dis Res. 2007;4:222-225.
87. Zhao YT, Weng CL, Chen ML, Li KB, Ge YG, Lin XM, Zhao WS, Chen J, Zhang L, Yin JX, Yang XC. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials. Heart. 2010;96:1622-1626.
88. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434-448.
89. Rame JE. Chronic heart failure: a reversible metabolic syndrome Circulation. 2012;125:2809-2811.
90. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol. 2009;54:1637-1646.
91. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125-2131.
92. Tuunanen H, Engblom E, Naum A, Nren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250-1258.
93. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441-2446.
94. Tuunanen H, Engblom E, Naum A, Scheinin M, Nren K, Airaksinen J, Nuutila P, Iozzo P, Ukkonen H, Knuuti J. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail. 2006;12:644-652.
95. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation: a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 2011;1813:1333-1350.
96. Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, Louis P, Rochette L, Girard C, Wolf JE. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail. 2002;4:181-184.
97. Alan S, Ulgen MS, Dedeoglu I, Kaya H, Toprak N. Long-term glucose insulin potassium infusion improves systolic and diastolic function in patients with chronic ischemic cardiomyopathy. Swiss Med Wkly. 2003;133:419-422.
98. Khoury VK, Haluska B, Prins J, Marwick TH. Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Heart. 2003;89:61-65.
99. Oldfield GS, Commerford PJ, Opie LH. Effects of preoperative glucoseinsulin-potassium on myocardial glycogen levels and on complications of mitral valve replacement. J Thorac Cardiovasc Surg. 1986;91: 874-878.
100. Howell NJ, Ashrafian H, Drury NE, Ranasinghe AM, Contractor H, Isackson H, Calvert M, Williams LK, Freemantle N, Quinn DW, Green D, Frenneaux M, Bonser RS, Mascaro JG, Graham TR, Rooney SJ, Wilson IC, Pagano D. Glucose-insulin- potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation. 2011;123:170-177.
101. Woods AA, Taegtmeyer H. Reversal of glucose-insulin-potassium-induced hyperglycemia by aggressive insulin treatment in postoperative heart failure: an observational study. Cardiology. 2004;102:82-88.